Introduction
Cytochrome P450 (CYP)3A is considered to be the most important enzyme group catalyzing drug metabolism because enzymes belonging to this family, particularly CYP3A4, are involved in the metabolism of 30-40% of currently prescribed drugs (Zanger et al., 2008) . Therefore, phenotyping of cytochrome CYP3A seems to be of special importance. Some CYP3A substrates such as midazolam, erythromycin, alprazolam and nifedipine; urinary 6β-hydroxycortisol to cortisol ratio; formation clearance of 6β-hydroxycortisol and 4β-hydroxycholesterol have been reported to be useful markers for CYP3A phenotyping (Bodin et al., 2001; Furuta et al., 2003; Galteau and Shamsa, 2003; Karayalçin et al., 1991; Kovacs et al., 1998; Streetman et al., 2000) . It is important to select the appropriate marker appropriate to the characteristics of the study subjects. Among them, 4β-hydroxycholesterol was first reported to be formed solely by CYP3A4 (Bodin et al., 2001 ). Markedly elevated concentrations of 4β-hydroxycholesterol were found in patients treated with CYP3A4 inducers (Niemi et al., 2006; Josephson et al., 2008; Wide et al., 2008; Diczfalusy et al., 2009; Goodenough et al., 2011) , and decreased concentrations in patients treated with CYP3A4 inhibitors (Josephson et al., 2008; Lütjohann et al., 2009; Goodenough et al., 2011) . Furthermore, a relationship between blood 4β-hydroxycholesterol concentration and the number of active CYP3A5*1 alleles has been demonstrated, suggesting that 4β-hydroxycholesterol is not only formed by CYP3A4, but also by CYP3A5 . Accordingly, 4β-hydroxycholesterol has been
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This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 17, 2013 as DOI: 10.1124 at ASPET Journals on June 24, 2017 dmd.aspetjournals.org Downloaded from 6 proposed to be a potential endogenous biomarker of CYP3A activity. Especially, 4β-hydroxycholesterol is useful in patients with renal failure because the kinetics of 4β-hydroxycholesterol is not affected by renal function (Bodin et al., 2002) .
Expression and function of CYP3A vary extensively both intra-and inter-individually, thus contributing to unpredictable drug response and toxicity. A multitude of environmental, genetic, and physiological factors are known to influence CYP3A4 expression and activity (Klein and Zanger, 2013) . Several studies in rats (Rege et al., 2003; Kusaba et al., 2012; Velenosi et al., 2012) and in patients (Dowling et al., 2003; Kirwan et al., 2009; have shown that renal failure decreases CYP3A expression and function. We have previously reported a significant increase in plasma concentration of 4β-hydroxycholesterol as an endogenous marker of CYP3A activity in patients with end stage renal disease after kidney transplantation (Suzuki et al., 2013) . The underlying causes of altered CYP expression and function observed in kidney disease remain unclear, but several studies indicate that uremic toxins may play a role via transcriptional or translational modifications of CYP enzymes and direct inhibition of CYP-mediated metabolism (Guévin et al., 2002; Hanada et al., 2006; Nolin et al., 2006; Michaud et al., 2008) . However, the relationship between the accumulation of uremic toxins and CYP3A activity in patients with renal failure remains unknown. In this study, we evaluated the relationship of CYP3A activity, using plasma concentration of 4β-hydroxycholesterol as a biomarker, with clinical characteristics including plasma concentrations of two uremic toxins, indoxyl sulfate (3-INDS) and indole-3-acetic acid (3-IAA), in stable kidney transplant recipients.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Patients. Forty-five Japanese kidney transplant recipients who underwent transplantation more than 90 days prior to the study were included. The study period was from January to June 2013. No recipient received medications known to inhibit or induce CYP3A (Huang et al., 2007) within three months before the study, and none were hemodialyzed. Morning blood samples were collected in tubes containing EDTA anticoagulant and all blood samples were centrifuged and plasma samples frozen at -40°C within 2 hours of peripheral venipuncture. The following clinical data was collected:
gender; age; body weight; prescribed drugs; and laboratory data including white blood cell count, hemoglobin, C-reactive protein, total cholesterol, alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), total bilirubin, serum creatinine and blood urea nitrogen. Creatinine clearance was calculated according to the Cockcroft-Gault equation (Cockcroft & Gault, 1976) . This study was approved by the ethics committee of Oita University. Each subject received information about the scientific purpose of the study, and gave written informed consent.
Measurement of plasma concentration of 4β-hydroxycholesterol. Plasma concentration of 4β-hydroxycholesterol was determined using a gas chromatography/mass spectrometry (GC/MS) system according to the procedures that we reported previously (Suzuki et al., 2013) . Inter-assay coefficients of variation for 20 and 200 ng/mL samples
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This article has not been copyedited and formatted. The final version may differ from this version. were 3.8 and 4.2%, respectively (n = 6). Intra-assay coefficients of variation for 20 and 200 ng/mL samples were 3.4 and 4.7%, respectively (n = 6). The lower limit of quantification was 1 ng/mL and the accuracy of the analysis ranged from 94.6 to 105.8%.
Measurement of plasma concentrations of 3-INDS and 3-IAA. Plasma concentrations of 3-INDS and 3-IAA were determined using a modification of the method previously reported (Calaf et al., 2011) . To 100 μ L of plasma in a polyethylene centrifuge tube, 300 μ L of 16 μ M p-ethylphenol in ethanol (internal standard) was added. Then, the plasma sample was saturated with 100 mg of NaCl and mixed for 10 min. After adding 700 μ L of mobile phase A (see below), the sample was centrifuged at 10000 g for 10 min. To Statistical analyses were performed using the R software version 2.14.2
(http://www.r-project.org) and the Predictive Analysis Software (PASW) Statistics version 21.0 (SPSS Inc., IL, USA).
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Relationships between renal function and plasma concentrations of uremic toxins.
Plasma concentrations (mean ± S.D.) of 3-INDS and 3-IAA were 10.9 ± 9.4 and 2.6 ± 1.4 variables associated with plasma concentration of 4β-hydroxycholesterol (Table 3) .
Discussion
To evaluate the CYP3A activity in human, the use of some CYP3A substrates have been proposed, including midazolam, erythromycin, alprazolam and nifedipine (Streetman et al., 2000) . However, these substrates have the problem of protein binding. For example, midazolam is normally 96% protein bound, and the unbound fraction may increase in
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As a traditional and safer method to evaluate CYP3A activity in patients, the urinary 6β-hydroxycortisol to cortisol ratio has been used as an endogenous biomarker of CYP3A (Karayalçin et al., 1991; Galteau et al., 2003) . However, this method depends on the renal clearance of both 6β-hydroxycortisol and cortisol as well as the formation clearance of 6β-hydroxycortisol. Therefore, urinary 6β-hydroxycortisol to cortisol ratio is a valid index of CYP3A activity only in the absence of significant intra-and inter-individual variations in cortisol renal clearance (Furuta et al., 2003) . As a result, this method is unsuitable for patients with renal failure. The formation clearance of 6β-hydroxycortisol has been proposed as a more accurate endogenous probe of CYP3A activity (Kovacs et al., 1998; Furuta et al., 2003; Galteau et al., 2003) . However, this method also has the problem of serum protein binding by cortisol, similar to midazolam. In the present study, we used plasma concentration of 4β-hydroxycholesterol to evaluate CYP3A activity in stable kidney transplant recipients. Since 4β-hydroxycholesterol is formed by CYP3A4 and 3A5 (Bodin et al., 2001; Diczfalusy et al., 2008) , this compound has been proposed to be a potential endogenous biomarker of CYP3A activity. Previous study has shown that 4β-hydroxycholesterol is slowly eliminated from the circulation probably due to slow 7α-hydroxylation (Bodin et al., 2002) , suggesting that the kinetics of 4β-hydroxycholesterol
This article has not been copyedited and formatted. The final version may differ from this version. activity in patients with end stage renal disease was significantly lower than that in controls. Kirwan et al. (2009; reported that increasing severity and duration of acute kidney injury were associated with decreased midazolam elimination. In addition, we have previously reported a significant increase in plasma concentration of 4β-hydroxycholesterol in patients with end stage renal disease after kidney transplantation (Suzuki et al., 2013) .
These reports suggest that CYP3A activity may depend on renal function.
Accumulation of retained uremic toxins is known to deteriorate renal function in chronic kidney disease, contributing to progression to renal failure. Studies have also suggest that uremic toxins may alter CYP expression and function via transcriptional or translational modifications of CYP enzymes and direct inhibition of CYP-mediated metabolism (Guévin et al., 2002; Hanada et al., 2006; Nolin et al., 2006; Michaud et al., 2008) . We hypothesized that accumulation of uremic toxins may contribute to reduction of CYP3A activity in patients with renal failure. To examine this hypothesis, we evaluated the relationship between CYP3A activity using plasma concentration of 4β-hydroxycholesterol
This article has not been copyedited and formatted. The final version may differ from this version. Therefore, we selected 3-INDS and 3-IAA as representative uremic toxins for this study.
First, our study showed that 11.1% patients were homozygous for the CYP3A5*1 allele (CYP3A5*1/*1) and 33.3% were heterozygous (CYP3A5*1/*3), while 55.6% were homozygous for the CYP3A5*3 allele (CYP3A5*3/*3). These distributions agreed with previous studies in Japanese (Fukuen et al., 2002; Hiratsuka et al., 2002; Saeki et al., 2003) .
Plasma concentration of 4β-hydroxycholesterol decreased significantly with increasing number of the CYP3A5*3 allele in the genotype as previously reported . This result suggests that CYP3A5 is involved primarily in the formation of 4β-hydroxycholesterol in Japanese stable kidney transplant recipients. Other polymorphisms of CYP3A5 such as CYP3A5*2, CYP3A5*4 and CYP3A5*5, and those of CYP3A4 such as CYP3A4*1B, CYP3A4*4, CYP3A4*16, CYP3A4*18 and CYP3A4*22
were not genotyped in this study because of the low frequencies of these genotypes in Japanese population (Lamba et al., 2002; Yamamoto et al., 2003; Goto et al., 2004; Nakajima et al., 2005; Hiratsuka et al., 2006; Okubo et al., 2013) . Further studies, probably across populations, would help to understand the effects of these polymorphisms on plasma concentration of 4β-hydroxycholesterol. Second, plasma concentrations of 3-INDS and 3-IAA were 10.9 ± 9.4 and 2.6 ± 1.4 μ M, respectively, consistent with previous reports in
This article has not been copyedited and formatted. The final version may differ from this version. patients with stages 3-5 chronic renal failure (Calaf et al., 2011) . A significant negative correlation was observed between creatinine clearance and plasma concentration of 3-INDS, also consistent with previous reports (Huang et al., 2012) . On the other hand, a mild but not significant negative correlation was observed between creatinine clearance and plasma concentration of 3-IAA. These results suggest that accumulation of 3-INDS, but not 3-IAA, is dependent of renal function in stable kidney transplant recipients. Third, a significant correlation was observed between plasma concentrations of 3-INDS and 4β-hydroxycholesterol but not between 3-IAA and 4β-hydroxycholesterol, suggesting that the accumulation of 3-INDS inhibits CYP3A activity or modifies CYP3A expression and decreases plasma concentration of 4β-hydroxycholesterol in stable kidney transplant recipients. A previous study showed that 3-INDS has a direct noncompetitive inhibitory effect on hepatic metabolism of various CYP3A substrates (Hanada et al., 2006) . This effect may be one of the mechanistic explanations for the association between CYP3A activity and 3-INDS. The reason why plasma concentration of 3-IAA did not correlate with that of 4β-hydroxycholesterol in vivo remains unclear, but the low plasma concentration and high inhibitory constant of 3-IAA compared to 3-INDS may be involved (Hanada et al., 2006) . Our study has a limitation. All recipients were administered cyclosporine or tacrolimus and methylprednisolone and some were administered mycophenolate mofetil or mizoribine as immunosuppressive therapy. It has been reported that cyclosporine and tacrolimus inhibit intestinal CYP3A activity mildly (Amundsen et al., 2012) , although mycophenolic acid, mizoribine and methylprednisolone do not inhibit or induce CYP3A (Konishi et al., 2004; Kagaya et al., 2008) . Therefore, there is a possibility that cyclosporine and tacrolimus may have affected CYP3A activity in this study. However, the kind of calcineurin inhibitor used Correlation of creatinine clearance with log plasma concentration of indoxyl sulfate (3-INDS) (a) and with log plasma concentration of indole-3-acetic acid (3-IAA) (b) in stable kidney transplant recipients.
Fig. 2
Plasma concentrations of 4β-hydroxycholesterol in stable kidney transplant recipients with CYP3A5*1/*1, *1/*3 and *3/*3 genotypes.
Bar indicates the median value.
Fig. 3
Correlation of log plasma concentration of indoxyl sulfate (3-INDS) (a) or indole-3-acetic acid (3-IAA) (b) with plasma concentration of 4β-hydroxycholesterol in stable kidney transplant recipients.
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